<DOC>
	<DOCNO>NCT00276692</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , irinotecan , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase II trial study well irinotecan work treat patient newly diagnose Ewing 's sarcoma .</brief_summary>
	<brief_title>Irinotecan Treating Patients With Newly Diagnosed Ewing 's Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess responsiveness single-agent irinotecan hydrochloride patient population newly diagnose high-risk Ewing 's sarcoma . OUTLINE : This open-label , multicenter study . Patients receive irinotecan hydrochloride IV 1 hour day 1 . Treatment repeat every 21 day 2 course . After completion 2 course therapy , patient may receive additional treatment discretion treat physician . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 35 patient accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm Ewing 's tumor Ewing 's sarcoma peripheral primitive neuroectodermal tumor bone soft tissue Highrisk disease ( R3 ) , define metastasis extrapulmonary/pleural site Newly diagnose disease Measurable primary and/or metastatic disease At least one bidimensionally measurable lesion Concurrent enrollment EUROEwing99 clinical trial require PATIENT CHARACTERISTICS : No abnormal cardiac function , include follow : Fractional shortening &lt; 29 % Ejection fraction &lt; 40 % Glomerular filtration rate â‰¥ 60mL/min Not pregnant Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment No prior current history chronic diarrhea , bowel obstruction , sub obstruction , Crohn 's disease , ulcerative colitis No medical , psychiatric , social condition incompatible study treatment PRIOR CONCURRENT THERAPY : No prior chemotherapy No 45 day since prior definitive biopsy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
</DOC>